JP2025060958A5 - - Google Patents
Info
- Publication number
- JP2025060958A5 JP2025060958A5 JP2024232254A JP2024232254A JP2025060958A5 JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5 JP 2024232254 A JP2024232254 A JP 2024232254A JP 2024232254 A JP2024232254 A JP 2024232254A JP 2025060958 A5 JP2025060958 A5 JP 2025060958A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- integrin
- rnai agent
- targeting ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663763P | 2018-04-27 | 2018-04-27 | |
| US62/663,763 | 2018-04-27 | ||
| US201962790372P | 2019-01-09 | 2019-01-09 | |
| US62/790,372 | 2019-01-09 | ||
| PCT/US2019/029393 WO2019210200A1 (en) | 2018-04-27 | 2019-04-26 | Integrin targeting ligands and uses thereof |
| JP2020560257A JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Division JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025060958A JP2025060958A (ja) | 2025-04-10 |
| JP2025060958A5 true JP2025060958A5 (https=) | 2025-10-08 |
Family
ID=68294255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
| JP2024232254A Pending JP2025060958A (ja) | 2018-04-27 | 2024-12-27 | インテグリン標的化リガンドとその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560257A Active JP7704529B2 (ja) | 2018-04-27 | 2019-04-26 | インテグリン標的化リガンドとその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210093725A1 (https=) |
| EP (2) | EP4435000A3 (https=) |
| JP (2) | JP7704529B2 (https=) |
| KR (1) | KR102787533B1 (https=) |
| CN (2) | CN118994152A (https=) |
| AU (1) | AU2019260738B2 (https=) |
| BR (1) | BR112020021949A2 (https=) |
| CA (1) | CA3097656A1 (https=) |
| DK (1) | DK3784269T3 (https=) |
| ES (1) | ES2983950T3 (https=) |
| FI (1) | FI3784269T3 (https=) |
| HR (1) | HRP20240907T1 (https=) |
| IL (2) | IL309955A (https=) |
| JO (1) | JOP20200266A1 (https=) |
| MX (1) | MX2020011290A (https=) |
| SA (1) | SA520420426B1 (https=) |
| SG (1) | SG11202009734VA (https=) |
| SI (1) | SI3784269T1 (https=) |
| TW (1) | TW202014206A (https=) |
| WO (1) | WO2019210200A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210093725A1 (en) * | 2018-04-27 | 2021-04-01 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| SG11202105577TA (en) | 2019-01-09 | 2021-06-29 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use |
| IL301187A (en) * | 2020-09-11 | 2023-05-01 | Arrowhead Pharmaceuticals Inc | RNAi agents for suppressing DUX4 expression, preparations containing them and uses thereof |
| EP4367246A2 (en) * | 2021-07-07 | 2024-05-15 | Alnylam Pharmaceuticals, Inc. | Integrin targeting ligands for ocular delivery of rnai compounds |
| CN121399119A (zh) * | 2023-06-19 | 2026-01-23 | 广东众生睿创生物科技有限公司 | 一种整合素配体及其用途 |
| WO2025252118A1 (zh) * | 2024-06-06 | 2025-12-11 | 苏州瑞博生物技术股份有限公司 | 整联蛋白αvβ6特异性配体化合物、缀合物、药物组合物及其用途 |
| WO2025261536A1 (zh) * | 2024-06-21 | 2025-12-26 | 长春金赛药业有限责任公司 | 一种整联蛋白配体关键中间体及其制备方法 |
| WO2026034639A1 (ja) * | 2024-08-09 | 2026-02-12 | 株式会社Spin Wave | ペプチド合成用可溶性担体およびこれを用いた合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES2241192T3 (es) * | 1997-12-17 | 2005-10-16 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Antagonistas del receptor de integrina. |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US20040224986A1 (en) * | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| CN102026671B (zh) * | 2008-03-14 | 2014-09-03 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
| BR112014016736A8 (pt) * | 2012-01-27 | 2017-07-04 | Hoffmann La Roche | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |
| CA2895430C (en) | 2013-01-28 | 2021-11-23 | Janssen Sciences Ireland Uc | Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents |
| SG10201706960TA (en) * | 2013-02-28 | 2017-10-30 | Arrowhead Res Corp | Organic compositions to treat epas1-related diseases |
| WO2015021092A1 (en) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| KR102647026B1 (ko) * | 2015-02-19 | 2024-03-12 | 사이플루어 라이프 사이언시즈, 인크 | 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 |
| US11971402B2 (en) * | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| KR20170141757A (ko) * | 2015-04-30 | 2017-12-26 | 사이플루어 라이프 사이언시즈, 인크 | 테트라하이드로나프티리디닐 프로피온산 유도체 및 이의 용도 |
| HK1252852A1 (zh) | 2015-05-29 | 2019-06-06 | Arrowhead Pharmaceuticals, Inc. | 阻止HIF2α基因表达的组合物及方法 |
| US20210093725A1 (en) * | 2018-04-27 | 2021-04-01 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
-
2019
- 2019-04-26 US US17/050,042 patent/US20210093725A1/en active Pending
- 2019-04-26 EP EP24179088.0A patent/EP4435000A3/en active Pending
- 2019-04-26 BR BR112020021949-5A patent/BR112020021949A2/pt unknown
- 2019-04-26 ES ES19794009T patent/ES2983950T3/es active Active
- 2019-04-26 KR KR1020207033772A patent/KR102787533B1/ko active Active
- 2019-04-26 IL IL309955A patent/IL309955A/en unknown
- 2019-04-26 CN CN202411099363.5A patent/CN118994152A/zh active Pending
- 2019-04-26 EP EP19794009.1A patent/EP3784269B1/en active Active
- 2019-04-26 CA CA3097656A patent/CA3097656A1/en active Pending
- 2019-04-26 SI SI201930780T patent/SI3784269T1/sl unknown
- 2019-04-26 SG SG11202009734VA patent/SG11202009734VA/en unknown
- 2019-04-26 MX MX2020011290A patent/MX2020011290A/es unknown
- 2019-04-26 JO JOP/2020/0266A patent/JOP20200266A1/ar unknown
- 2019-04-26 AU AU2019260738A patent/AU2019260738B2/en active Active
- 2019-04-26 WO PCT/US2019/029393 patent/WO2019210200A1/en not_active Ceased
- 2019-04-26 FI FIEP19794009.1T patent/FI3784269T3/fi active
- 2019-04-26 JP JP2020560257A patent/JP7704529B2/ja active Active
- 2019-04-26 IL IL278304A patent/IL278304B2/en unknown
- 2019-04-26 DK DK19794009.1T patent/DK3784269T3/da active
- 2019-04-26 CN CN201980028704.0A patent/CN112074290B/zh active Active
- 2019-04-26 HR HRP20240907TT patent/HRP20240907T1/hr unknown
- 2019-04-29 TW TW108114935A patent/TW202014206A/zh unknown
-
2020
- 2020-10-27 SA SA520420426A patent/SA520420426B1/ar unknown
-
2024
- 2024-12-27 JP JP2024232254A patent/JP2025060958A/ja active Pending